Newborns suffering from ultra-rare and fatal genetic disorder now have chance at life

By Team VIVA! | February 23, 2011

Newborns with the ultra-rare and fatal genetic disorder – molybdenum cofactor deficiency (MoCD) Type A – now have a chance at life after Alexion Pharmaceuticals, Inc. purchased the assets and patents from Orphatec Pharmaceuticals GmbH, in order to accelerate the development of an investigational therapy to cure the fatal disorder.  MoCD Type A is characterised…

Read More

Buyer beware

By Team VIVA! | January 27, 2011 |

Ask questions before you buy  The Team VIVA! ladies love to bag a bargain (shoes seem to be a common weakness) and we pride ourselves on spotting a sale a mile away! Needless to say, we were surprised to learn  that nearly two-thirds (38 per cent) of generic medicines are actually no cheaper than their…

Read More

Future of NSW residents’ health under threat

By Team VIVA! | January 24, 2011

Team VIVA! were shocked to hear about the NSW Government’s plans to sell off sections of the Royal North Shore Hospital (RNSH) campus. VIVA! HQ is located in Chatswood, making RNSH our local hospital, should anything dire ever happen (touch wood). The idea that significant parcels of land are earmarked for sale has both shocked…

Read More